Aura Biosciences completes CoMpass treatment visits, confirms 2H 2027 data timing

Aura Biosciences reported on November 9, 2026 that its Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) in early choroidal melanoma has reached a key operational milestone. Enrollment is complete with 108 participants in the trial, and as of the third quarter of 2026, all participants have completed their treatment regimen and are now in the 24-month follow-up observation period.¹ The trial remains on track to deliver topline data from the 15-month primary endpoint in the second half of 2027.¹

The study operates under a Special Protocol Assessment agreement with the FDA, which represents alignment on the trial design and planned analyses to support a potential Biologics License Application for bel-sar.¹

On the manufacturing side, Aura established a new supply relationship during the quarter with a contract development and manufacturing organization experienced in viral vector-based medicinal products, with the companies establishing capacity designated for bel-sar development and commercial supply.¹

Beyond the lead program, Aura continues to advance bel-sar in metastases to the choroid and cancers of the ocular surface in early clinical trials, with an update on both programs expected in the first quarter of 2027.¹

On financing, Aura held cash, cash equivalents and marketable securities totaling $297.2 million as of September 30, 2026, which the company said is sufficient to fund operations into the first half of 2029.¹ The quarter also included a completed restructuring: the company incurred restructuring charges of approximately $4.5 million tied to aligning resources behind its ocular oncology portfolio, a plan completed in the third quarter of 2026.¹

Aura will host an investor event on early choroidal melanoma on December 8, 2026, joined by Dr. Arun Singh, Director of the Department of Ophthalmic Oncology in the Cole Eye Institute of the Cleveland Clinic.¹